FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS Share Price

Certificat

DE000MG3DZD6

Real-time Bid/Ask 09:13:32 19/06/2024 BST
9.61 EUR / 9.84 EUR -0.46% Intraday chart for FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS
Current month-20.63%
1 month-29.31%
Date Price Change
19/06/24 9.6 -1.74%
18/06/24 9.77 +1.24%
17/06/24 9.65 -1.23%
14/06/24 9.77 +4.49%
13/06/24 9.35 -7.88%

Delayed Quote Börse Stuttgart

Last update June 19, 2024 at 08:03 am

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying IONIS PHARMACEUTICALS, INC.
Issuer Morgan Stanley
WKN MG3DZD
ISINDE000MG3DZD6
Date issued 30/04/2024
Strike 54.19 $
Maturity Unlimited
Parity 1.31 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 14.11
Lowest since issue 8.31
Spread 0.23
Spread %2.34%

Company Profile

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Sector
-
More about the company

Ratings for Ionis Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Ionis Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
40.64 USD
Average target price
58.04 USD
Spread / Average Target
+42.80%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW